GUANGZHOU, China I February 1, 2024 I Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that dosing has begun in Phase IA/IIB clinical trial to study efficacy and safety of BAT6026 in patients with moderate to severe atopic dermatitis.
OX40 is an important autoimmune and inflammatory drug target, as OX40 is highly expressed by activated CD4+ and CD8+ T cells, which play an important role in many inflammatory diseases, such as atopic dermatitis (AD). BAT6026 not only blocks the OX40/OX40L interaction to prevent T cell activation and proliferation, but also specifically depletes activated OX40+ T cells through enhanced ADCC effect. Therefore, BAT6026 is expected to treat many inflammatory diseases, including those mediated by Th2 cells. BAT6026 has an exciting preclinical profile and was shown to be safe and well tolerated in a Phase 1 dose escalation clinical study.
The Phase IA/IIB, multicenter clinical trial of BAT6026 is designed to assess the efficacy and safety of BAT6026 in patients with moderate to severe atopic dermatitis. Key objectives in the study include determining safety, tolerability, pharmacokinetics, and preliminary anti-inflammatory activity.
About Bio-Thera Solutions
Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next generation antibody discovery and engineering, the company has advanced multiple candidates into late-stage development, including three approved products: QLETLI® in China, and TOFIDENCE™/ BAT1806 and Avzivi®/Pobevcy® in the US and China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as ADCs. For more information, please visit www.bio-thera.com/en/or follow us on Twitter (@bio_thera_sol) and WeChat (Bio-Thera).
SOURCE: Bio-Thera Solutions
Post Views: 114
GUANGZHOU, China I February 1, 2024 I Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that dosing has begun in Phase IA/IIB clinical trial to study efficacy and safety of BAT6026 in patients with moderate to severe atopic dermatitis.
OX40 is an important autoimmune and inflammatory drug target, as OX40 is highly expressed by activated CD4+ and CD8+ T cells, which play an important role in many inflammatory diseases, such as atopic dermatitis (AD). BAT6026 not only blocks the OX40/OX40L interaction to prevent T cell activation and proliferation, but also specifically depletes activated OX40+ T cells through enhanced ADCC effect. Therefore, BAT6026 is expected to treat many inflammatory diseases, including those mediated by Th2 cells. BAT6026 has an exciting preclinical profile and was shown to be safe and well tolerated in a Phase 1 dose escalation clinical study.
The Phase IA/IIB, multicenter clinical trial of BAT6026 is designed to assess the efficacy and safety of BAT6026 in patients with moderate to severe atopic dermatitis. Key objectives in the study include determining safety, tolerability, pharmacokinetics, and preliminary anti-inflammatory activity.
About Bio-Thera Solutions
Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next generation antibody discovery and engineering, the company has advanced multiple candidates into late-stage development, including three approved products: QLETLI® in China, and TOFIDENCE™/ BAT1806 and Avzivi®/Pobevcy® in the US and China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as ADCs. For more information, please visit www.bio-thera.com/en/or follow us on Twitter (@bio_thera_sol) and WeChat (Bio-Thera).
SOURCE: Bio-Thera Solutions
Post Views: 114
